Breakingviews - COMMENTARY: GSK is two shots away from clean bill of health

One of Europe’s most cheaply valued ​drugmakers, the £75 bln ​group run by Luke Miels ⁠is turning a corner. ​Fears over expiring patents ​are easing thanks to a booming oncology unit. A £40 bln sales...